DekaBank Deutsche Girozentrale Buys 4,117 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

DekaBank Deutsche Girozentrale lifted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 163.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 6,634 shares of the medical equipment provider’s stock after acquiring an additional 4,117 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Lantheus were worth $410,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Silverberg Bernstein Capital Management LLC bought a new stake in shares of Lantheus during the 4th quarter worth $1,385,000. Natixis Advisors L.P. lifted its holdings in shares of Lantheus by 172.8% during the 3rd quarter. Natixis Advisors L.P. now owns 52,530 shares of the medical equipment provider’s stock worth $3,649,000 after acquiring an additional 33,273 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Lantheus by 41.9% during the 3rd quarter. American Century Companies Inc. now owns 1,300,904 shares of the medical equipment provider’s stock worth $90,387,000 after acquiring an additional 384,093 shares during the last quarter. Boston Partners lifted its stake in Lantheus by 15.2% in the third quarter. Boston Partners now owns 512,930 shares of the medical equipment provider’s stock worth $35,326,000 after purchasing an additional 67,729 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its stake in Lantheus by 60.5% in the third quarter. Lazard Asset Management LLC now owns 336,946 shares of the medical equipment provider’s stock worth $23,410,000 after purchasing an additional 126,947 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Lantheus Trading Down 0.9 %

Shares of LNTH opened at $60.25 on Tuesday. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $100.85. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69. The firm’s 50-day moving average price is $60.25 and its 200-day moving average price is $63.06. The firm has a market capitalization of $4.13 billion, a price-to-earnings ratio of 12.98 and a beta of 0.54.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, beating the consensus estimate of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The business had revenue of $354.00 million for the quarter, compared to analysts’ expectations of $350.44 million. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 5.72 EPS for the current year.

Analyst Ratings Changes

LNTH has been the subject of several recent research reports. William Blair downgraded shares of Lantheus from an “outperform” rating to a “market perform” rating in a research note on Monday, December 18th. B. Riley lowered their price target on shares of Lantheus from $113.00 to $95.00 and set a “buy” rating for the company in a research note on Wednesday, January 10th. JMP Securities reissued a “market outperform” rating and issued a $100.00 price target on shares of Lantheus in a research note on Friday, February 23rd. TheStreet downgraded shares of Lantheus from a “b-” rating to a “c” rating in a research note on Monday, December 18th. Finally, StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $104.14.

Insider Buying and Selling

In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the acquisition, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The purchase was disclosed in a filing with the SEC, which is available at this link. In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were purchased at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the transaction, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. 2.10% of the stock is owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.